Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04362111
Other study ID # Chatham-Cytokine Covid-19
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date August 1, 2020
Est. completion date June 1, 2023

Study information

Verified date August 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.


Description:

The first aim of this project is to determine whether rapidly assayed early clinical laboratory markers of CSS (eCSS: leucopenia, lymphopenia, and elevated ferritin, d-dimer, LDH, CRP, and AST/ALT) in patients admitted to the hospital with respiratory compromise in the setting of Covid-19 infection can accurately identify patients with CSS as defined by validated CSS case definitions (H-Score, aHLH-2004). Confirmation of eCSS predictive of evolving CSS will identify patients at risk for rapid deterioration of lung function and inform early initiation of treatment for CSS. Genotyping studies will also be performed on patients with confirmed CSS to determine whether perforin pathway mutations commonly present in CSS associated with other disorders are present. The second aim is to determine whether early treatment with rhIL-1Ra (anakinra) in patients admitted to the hospital with markers of CSS improves or prevents deterioration of respiratory dysfunction and prevents the development of respiratory failure requiring mechanical ventilation.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date June 1, 2023
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. 18 years old or older 2. Molecular (pcRNA) diagnosis of SARS-CoV-2 infection 3. Chest imaging studies consistent with Covid-19 pneumonia 4. Hyperferritinemia (>700 ng/ml) 5. History of fever >38 degrees C 6. Any three of the following: 1. Elevated d-dimer (> 500 ng/ml) 2. thrombocytopenia (< 130,000/mm3) 3. leucopenia (WBC <3500/mm3) or lymphopenia (<1000/mm3) 4. elevated AST or ALT (> 2X ULN) 5. elevated LDH (> 2X ULN) 6. CRP > 100 mg/L Exclusion Criteria: 1. Participation in other investigational treatment protocols for Covid-19 infection 2. Culture confirmed active bacterial infection requiring antibiotic therapy 3. On mechanical ventilation 4. Previous known hypersensitivity reaction to anakinra 5. Previous known hypersensitivity reaction to E Coli derived proteins 6. Pregnant or breast-feeding females

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anakinra
The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days
Normal saline
The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation. Percentage of subjects discharged from hospital alive and who did not require intubation and mechanical ventilation Variable up to Day 28
Secondary Percentage of Subjects With 25% Change (Decrease) in Cytokine Storm Markers at 48-72 Hours After Dosing With Study Agent 25% change (decrease) in noted baseline elevations of serum ferritin and CRP measured 48-72 hours after following initial dosing of anakinra/placebo. 48 hours after taking initial dose of anakinra/placebo
Secondary Percentage of Subjects Without Increase in Oxygen Requirement and no Increase in Oxygen Delivery/Respiratory Support Measures After 48 Hours. Supplemental oxygen requirement to maintain oxygen saturation >90% stable or decreased without escalation of respiratory support measures (addition of CPAP, initiation of mechanical ventilation) Day 2 (48 hours)-Day 10 (240 hours)
Secondary Patients Requiring Minimal Oxygen Support at Day 10 Percentage of participants requiring no more than 2 L/min nasal canula oxygen to maintain oxygen saturation >93% by Day 10 0-10 days
Secondary Percentage of Subjects With Resolution of Laboratory Markers of Cytokine Storm Syndrome Normalization or = 75% improvement by Day 10 (120 hours) in each (all) of the following laboratory CSS attributes elevated beyond the normal range at randomization: ferritin, d-dimer, CRP, and LDH. Day 10
Secondary Percentage of Subjects Who Develop Bacterial or Fungal or Non-Covid-19 Viral Infection Occurence of new bacterial or fungal or viral infection through the time of hospital discharge or Day 28. Day 0-28
Secondary Absence of Supplemental Oxygen Requirement at Day 10 Percentage of participants able to maintain oxygen saturation >93% on room air by Day 10 0-10 Days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure